Radiation Toxicity Radiation Sickness, Acute Radiation Syndrome-Pipeline Review, H1 2016

Radiation Toxicity Radiation Sickness, Acute Radiation Syndrome-Pipeline Review, H1 2016


  • Products Id :- GMDHC7705IDB
  • |
  • Pages: 216
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H1 2016', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects

The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 9

Therapeutics Development 10

Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Overview 10

Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Comparative Analysis 11

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics under Development by Companies 12

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics under Investigation by Universities/Institutes 16

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Products under Development by Companies 21

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Products under Investigation by Universities/Institutes 25

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Companies Involved in Therapeutics Development 26

Aeolus Pharmaceuticals, Inc. 26

Angion Biomedica Corp. 27

Atox Bio Inc. 28

Avaxia Biologics, Inc. 29

Bolder Biotechnology, Inc. 30

Caladrius Biosciences, Inc. 31

Cellerant Therapeutics, Inc. 32

Cellphire, Inc. 33

Chrysalis BioTherapeutics, Inc. 34

Cleveland BioLabs, Inc. 35

Cumberland Pharmaceuticals, Inc. 36

Diffusion Pharmaceuticals Inc. 37

Eli Lilly and Company 38

GNI Group Ltd. 39

Humanetics Corporation 40

INSYS Therapeutics, Inc. 41

Meabco A/S 42

Neumedicines Inc. 43

Onconova Therapeutics, Inc. 44

PharmaIN Corporation 45

Pluristem Therapeutics Inc. 46

ProCertus BioPharm Inc. 47

RDD Pharma Ltd. 48

RedHill Biopharma Ltd. 49

RxBio, Inc. 50

Soligenix, Inc. 51

Stemedica Cell Technologies, Inc. 52

Terapio Corporation 53

Tonix Pharmaceuticals Holding Corp. 54

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Target 56

Assessment by Mechanism of Action 59

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

AB-103-Drug Profile 66

ABC-294640-Drug Profile 68

AEOL-10150-Drug Profile 71

AEOL-10171-Drug Profile 75

Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis-Drug Profile 76

AVMOC-001-Drug Profile 77

AVX-470-Drug Profile 78

BB-3-Drug Profile 80

BBT-007-Drug Profile 84

BBT-015-Drug Profile 85

BBT-018-Drug Profile 86

BBT-059-Drug Profile 87

BCN-057-Drug Profile 88

BIO-300-Drug Profile 89

BMX-001-Drug Profile 92

BPC-2-Drug Profile 93

C-2E2-Drug Profile 94

C-2E5-Drug Profile 95

CBLB-613-Drug Profile 96

CLT-009-Drug Profile 97

EDL-2000-Drug Profile 98

entolimod-Drug Profile 99

EWA-001-Drug Profile 101

HSJ-0017-Drug Profile 102

JP4-039-Drug Profile 103

LGM-2605-Drug Profile 105

LY-2109761-Drug Profile 106

m2A2-Drug Profile 107

NMIL-121-Drug Profile 108

ondansetron hydrochloride-Drug Profile 110

ondansetron hydrochloride CR-Drug Profile 111

Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke-Drug Profile 113

pirfenidone-Drug Profile 115

PLXR-18-Drug Profile 116

PrC-210-Drug Profile 119

RDD-2007-Drug Profile 120

recilisib sodium-Drug Profile 121

Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity-Drug Profile 123

Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury-Drug Profile 124

Recombinant Protein to Activate FGF-4 for Radiation Injury-Drug Profile 126

Recombinant Protein to Activate FGF-7 for Radiation Injury-Drug Profile 127

RES-529-Drug Profile 128

RP-239X-Drug Profile 131

rusalatide acetate-Drug Profile 132

Rx-100-Drug Profile 136

RX-101-Drug Profile 138

SGX-201-Drug Profile 139

SGX-202-Drug Profile 140

Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury-Drug Profile 141

Small Molecules for Radiation and Chemical Toxicity-Drug Profile 142

Small Molecules for Radiation Toxicity-Drug Profile 143

Small Molecules to Activate Vitamin D Receptor for Radiation Injury-Drug Profile 144

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology-Drug Profile 145

ST-7-Drug Profile 146

Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology-Drug Profile 147

Stem Cell Therapy for Radiation Exposure-Drug Profile 149

SY-303A-Drug Profile 150

SY-513-Drug Profile 151

SYGN-305P-Drug Profile 152

SYGN-399-Drug Profile 153

Thrombosomes-Drug Profile 154

TPO-7630-Drug Profile 155

TPO-7640-Drug Profile 157

VEDA-1209-Drug Profile 158

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Recent Pipeline Updates 159

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects 199

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Discontinued Products 203

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Product Development Milestones 204

Featured News & Press Releases 204

Appendix 211

Methodology 211

Coverage 211

Secondary Research 211

Primary Research 211

Expert Panel Validation 211

Contact Us 211

Disclaimer 212

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2016 14

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Number of Products under Investigation by Universities/Institutes, H1 2016 20

Comparative Analysis by Late Stage Development, H1 2016 21

Comparative Analysis by Clinical Stage Development, H1 2016 22

Comparative Analysis by Early Stage Products, H1 2016 23

Assessment by Monotherapy Products, H1 2016 59

Number of Products by Top 10 Targets, H1 2016 60

Number of Products by Stage and Top 10 Targets, H1 2016 60

Number of Products by Top 10 Mechanism of Actions, H1 2016 63

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 63

Number of Products by Top 10 Routes of Administration, H1 2016 66

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 66

Number of Products by Top 10 Molecule Types, H1 2016 68

Number of Products by Stage and Top 10 Molecule Types, H1 2016 68

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2016 14

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 17

Number of Products under Development by Companies, H1 2016 (Contd..1) 18

Number of Products under Development by Companies, H1 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2016 20

Comparative Analysis by Late Stage Development, H1 2016 21

Comparative Analysis by Clinical Stage Development, H1 2016 22

Comparative Analysis by Early Stage Development, H1 2016 23

Comparative Analysis by Unknown Stage Development, H1 2016 24

Products under Development by Companies, H1 2016 25

Products under Development by Companies, H1 2016 (Contd..1) 26

Products under Development by Companies, H1 2016 (Contd..2) 27

Products under Development by Companies, H1 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2016 29

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 30

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Angion Biomedica Corp., H1 2016 31

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Atox Bio Inc., H1 2016 32

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Avaxia Biologics, Inc., H1 2016 33

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Bolder Biotechnology, Inc., H1 2016 34

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Caladrius Biosciences, Inc. , H1 2016 35

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellerant Therapeutics, Inc., H1 2016 36

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellphire, Inc., H1 2016 37

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Chrysalis BioTherapeutics, Inc., H1 2016 38

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cleveland BioLabs, Inc., H1 2016 39

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cumberland Pharmaceuticals, Inc., H1 2016 40

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 41

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Eli Lilly and Company, H1 2016 42

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by GNI Group Ltd., H1 2016 43

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Humanetics Corporation, H1 2016 44

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by INSYS Therapeutics, Inc., H1 2016 45

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Meabco A/S, H1 2016 46

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Neumedicines Inc., H1 2016 47

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Onconova Therapeutics, Inc., H1 2016 48

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by PharmaIN Corporation, H1 2016 49

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Pluristem Therapeutics Inc., H1 2016 50

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by ProCertus BioPharm Inc., H1 2016 51

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RDD Pharma Ltd., H1 2016 52

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RedHill Biopharma Ltd., H1 2016 53

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RxBio, Inc., H1 2016 54

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Soligenix, Inc., H1 2016 55

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Stemedica Cell Technologies, Inc., H1 2016 56

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Terapio Corporation, H1 2016 57

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 58

Assessment by Monotherapy Products, H1 2016 59

Number of Products by Stage and Target, H1 2016 61

Number of Products by Stage and Mechanism of Action, H1 2016 64

Number of Products by Stage and Route of Administration, H1 2016 67

Number of Products by Stage and Molecule Type, H1 2016 69

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics-Recent Pipeline Updates, H1 2016 163

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H1 2016 203

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects (Contd..1), H1 2016 204

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects (Contd..2), H1 2016 205

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects (Contd..3), H1 2016 206

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Discontinued Products, H1 2016 207

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aeolus Pharmaceuticals, Inc. Angion Biomedica Corp. Atox Bio Inc. Avaxia Biologics, Inc. Bolder Biotechnology, Inc. Caladrius Biosciences, Inc. Cellerant Therapeutics, Inc. Cellphire, Inc. Chrysalis BioTherapeutics, Inc. Cleveland BioLabs, Inc. Cumberland Pharmaceuticals, Inc. Diffusion Pharmaceuticals Inc. Eli Lilly and Company GNI Group Ltd. Humanetics Corporation INSYS Therapeutics, Inc. Meabco A/S Neumedicines Inc. Onconova Therapeutics, Inc. PharmaIN Corporation Pluristem Therapeutics Inc. ProCertus BioPharm Inc. RDD Pharma Ltd. RedHill Biopharma Ltd. RxBio, Inc. Soligenix, Inc. Stemedica Cell Technologies, Inc. Terapio Corporation Tonix Pharmaceuticals Holding Corp.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Products under Development, Key Players in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Overview, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143120
Site License
USD 4000 INR 286240
Corporate User License
USD 6000 INR 429360

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com